

AZD2281

# STUDY 8

In colorectal cancer

A phase II, open-label, multicenter clinical trial to assess the efficacy and safety of the PARP inhibitor, olaparib, alone in previously-treated patients with stage IV, measurable colorectal cancer, stratified by MSI status

**Purpose:** To assess if AZD2281 can effectively and safely treat advanced large bowel cancer. The primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient's cancer by causing a response and increasing the time it takes for the cancer to progress

**Primary endpoint:** Tumor response as assessed by RECIST

**Participating countries:** United States

*AZD2281 is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.*

For more information,  
please contact:

Cancer Study Locator service, sponsored by  
AstraZeneca at 1-877-400-4656  
Or via e-mail at: [astrazeneca@emergingmed.com](mailto:astrazeneca@emergingmed.com)  
To find available investigator site details, go to: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

AstraZeneca 

AstraZeneca Pharmaceuticals, LP  
Wilmington, Delaware  
[www.astrazeneca.com](http://www.astrazeneca.com)